



## Compatibility of Age-Appropriate Compounded Oral Suspensions

Marios G. Kostakis<sup>1</sup>, MSc, PhD; Anastasia Koupa<sup>1</sup>, MSc; Nikolaos S. Thomaidis<sup>1</sup>, PhD; Paraskevas Dalla<sup>2</sup>, MSc, PhD; Carolina C.V. Silva<sup>3</sup>, PhD; Carolina Kegele<sup>3</sup>, MSc; Eli Dijkers<sup>3</sup>, PharmD, PhD, hospital pharmacist; Maria Kousteliou<sup>3</sup>, MSc; Savvas Kouloridas<sup>3</sup>, MSc; Konstantinos Kouloridas<sup>3</sup>, MSc; Hudson C. Polonini<sup>3,\*</sup>, MSc, PhD.

## What was done and why


- Oral administration is the primary route for drug delivery.
- Standard medications often fail to meet the needs of neonates, infants, children, and older adults.
- Challenges include dose adjustments, swallowing difficulties, inaccurate dosing, and reduced drug stability.
- Compounded medications offer a tailored alternative for individual patient needs.
- This study assesses the compatibility of oral suspensions with SyrSpend® SF across nine pharmacological classes.


## How it was done

- Twenty-two APIs were compounded with SyrSpend® SF PH4 liquid.
- Storage conditions: refrigerated (2-8°C), and room temperature (20-25°C).
- Compatibility assessment: monitored over 90 days.
- Analysis method: stabilityindicating HPLC-UV measuring percent recovery.

## What was achieved

- Most compounded suspensions remained stable for 90 days under refrigeration and at room temperature for up to 90 days.
- Cimetidine required adjustment to pH~4 during compounding.
- Detailed stability results are shown in figure 1.





<sup>1</sup>Laboratory of Analytical Chemistry, Department of Chemistry, School of Science, National and Kapodistrian University of Athens, Athens, Greece.

<sup>2</sup>Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Science, National and Kapodistrian University of Athens, Athens, Greece.

<sup>3</sup>Fagron BV – Rotterdam, The Netherlands. \*Corresponding author: hudson.polonini@fagron.com